Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,436 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00001249 | Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001333 | Phase I Study of Intrathecal Topotecan | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001336 |
| In Vitro Studies of Immunological and Stem Cell Function in Peripheral Blood Mononuclear Cells in Patients |
| completed |
| — |
| 1,000 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Mar 4, 2008 |
| clinicaltrials |
| NCT00001424 | Evaluation and Natural History of Children With Cancer and AIDS | completed | — | 110 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001432 | The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies | completed | — | 75 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001567 | A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001689 | A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia | completed | Phase 1 | 90 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001748 | HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies | completed | Phase 1 | 35 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00363025 | A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. | terminated | Phase 3 | 465 | Acute Leukemia French AssociationOTHER | 1 | Feb 21, 2008 | clinicaltrials |
| NCT00274248 | MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia | completed | Phase 1 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00304720 | Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor | unknown | Phase 2 | 40 | Colorado Blood Cancer InstituteOTHER | 1 | Feb 8, 2008 | clinicaltrials |
| NCT00599937 | APL93: Timing of CxT and Role of Maintenance | completed | Phase 3 | 576 | Groupe d'etude et de travail sur les leucemies aigues promyelocytairesOTHER | 0 | Jan 24, 2008 | clinicaltrials |
| NCT00104468 | Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 50 | SGX Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 17, 2008 | clinicaltrials |
| NCT00591526 | A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL) | completed | Phase 3 | 250 | Groupe d'etude et de travail sur les leucemies aigues promyelocytairesOTHER | 0 | Jan 14, 2008 | clinicaltrials |
| NCT00077493 | BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma | suspended | Phase 1 | 95 | MedImmune LLCINDUSTRY | 1 | Dec 28, 2007 | clinicaltrials |
| NCT00165087 | Treatment of Childhood Acute Lymphoblastic Leukemia | terminated | Phase 3 | 491 | Dana-Farber Cancer InstituteOTHER | 3 | Dec 28, 2007 | clinicaltrials |
| NCT00116467 | Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia | completed | Phase 2 | 55 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00271063 | Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia | unknown | Phase 1 / Phase 2 | 34 | Callisto PharmaceuticalsINDUSTRY | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00041990 | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec) | completed | Phase 2 | 40 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 17, 2007 | clinicaltrials |
| NCT00566566 | Adipokines as Predictors of the Metabolic Syndrome in ALL Survivors | unknown | — | 150 | Sheba Medical CenterOTHER_GOV | 0 | Dec 3, 2007 | clinicaltrials |
| NCT00552825 | Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children | completed | — | 35 | Sheba Medical CenterOTHER_GOV | 1 | Nov 2, 2007 | clinicaltrials |
| NCT00535912 | Phase III Study Treatment of CLL B and C | completed | Phase 3 | 140 | French Innovative Leukemia OrganisationOTHER | 0 | Nov 1, 2007 | clinicaltrials |
| NCT00196768 | Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic | unknown | Phase 4 | 30 | German AML Cooperative GroupOTHER | 1 | Oct 23, 2007 | clinicaltrials |
| NCT00297570 | Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy | unknown | Phase 3 | 90 | Sheba Medical CenterOTHER_GOV | 1 | Oct 10, 2007 | clinicaltrials |
| NCT00537550 | Adult ALL Treatment at Diagnosis(LAL2000) | completed | N/A | — | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Oct 1, 2007 | clinicaltrials |
| NCT00529880 | Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML | unknown | Phase 2 | 19 | Cooperative Study Group A for HematologyNETWORK | 1 | Sep 27, 2007 | clinicaltrials |
| NCT00526084 | Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan | unknown | — | 500 | National Taiwan University HospitalOTHER | 1 | Sep 6, 2007 | clinicaltrials |
| NCT00517712 | Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia(IAPLSG04) | unknown | Phase 2 / Phase 3 | 400 | Christian Medical College, Vellore, IndiaOTHER | 1 | Aug 17, 2007 | clinicaltrials |
| NCT00515892 | Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease(NHL) | unknown | Phase 1 | 50 | Cambridge Antibody TechnologyOTHER | 2 | Aug 14, 2007 | clinicaltrials |
| NCT00514488 | Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day)(CML022) | completed | Phase 3 | — | University of BolognaOTHER | 1 | Aug 10, 2007 | clinicaltrials |
| NCT00514969 | Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase(CML003) | completed | Phase 2 | — | University of BolognaOTHER | 1 | Aug 10, 2007 | clinicaltrials |
| NCT00510926 | Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase | completed | Phase 2 | 80 | University of BolognaOTHER | 1 | Aug 3, 2007 | clinicaltrials |
| NCT00511121 | Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON) | terminated | Phase 2 | 5 | University of BolognaOTHER | 0 | Aug 3, 2007 | clinicaltrials |
| NCT00511303 | Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia | completed | Phase 2 | 200 | University of BolognaOTHER | 0 | Aug 3, 2007 | clinicaltrials |
| NCT00145652 | Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders. | completed | Phase 3 | 66 | Sundsvall HospitalOTHER | 1 | Jul 30, 2007 | clinicaltrials |
| NCT00505141 | Urban Environmental Exposures and Childhood Cancer | completed | — | — | Georgetown UniversityOTHER | 1 | Jul 23, 2007 | clinicaltrials |
| NCT00180115 | AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients | completed | Phase 4 | 400 | Technische Universität DresdenOTHER | 1 | Jul 17, 2007 | clinicaltrials |
| NCT00105313 | Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia | terminated | Phase 1 | 80 | MedImmune LLCINDUSTRY | 1 | Jun 14, 2007 | clinicaltrials |
| NCT00483132 | Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III | completed | Phase 3 | 232 | French Innovative Leukemia OrganisationOTHER | 1 | Jun 6, 2007 | clinicaltrials |
| NCT00480064 | Lomustine and Intermediate Dose Cytarabine in Older Patients With AML | completed | Phase 3 | 360 | French Innovative Leukemia OrganisationOTHER | 1 | May 30, 2007 | clinicaltrials |
| NCT00126893 | Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia | terminated | Phase 1 | 36 | Celgene CorporationINDUSTRY | 1 | May 15, 2007 | clinicaltrials |
| NCT00109356 | Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia | unknown | Phase 1 / Phase 2 | 55 | NovaceaINDUSTRY | 1 | May 7, 2007 | clinicaltrials |
| NCT00146913 | AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year | unknown | Phase 2 | 30 | Hospices Civils de LyonOTHER | 1 | Apr 27, 2007 | clinicaltrials |
| NCT00149136 | Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy. | unknown | Phase 2 | 30 | Hospices Civils de LyonOTHER | 1 | Apr 27, 2007 | clinicaltrials |
| NCT00299780 | Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization. | completed | Phase 1 | 12 | Massachusetts General HospitalOTHER | 1 | Apr 24, 2007 | clinicaltrials |
| NCT00143884 | Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood | terminated | Phase 2 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 23, 2007 | clinicaltrials |
| NCT00462189 | Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease | unknown | Phase 1 | 40 | Cambridge Antibody TechnologyOTHER | 3 | Apr 18, 2007 | clinicaltrials |
| NCT00457860 | Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease | unknown | Phase 1 | 50 | Cambridge Antibody TechnologyOTHER | 2 | Apr 17, 2007 | clinicaltrials |
| NCT00460447 | Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | University Hospital Carl Gustav CarusOTHER | 1 | Apr 16, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Mar 4, 2008source: clinicaltrials